Arena Pharmaceuticals' BELVIQ(R) (lorcaserin HCl) CIV Nominated for 2013 Prix Galien USA Award
SAN DIEGO, July 25, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that BELVIQ® (lorcaserin HCl) has been nominated for the 2013 Prix Galien USA Award in the Best Pharmaceutical Agent category. BELVIQ is approved by the US Food and Drug Administration (FDA) for chronic weight management in adults.
The Prix Galien Award is considered one of the biomedical industry's top accolades, as it recognizes outstanding achievements in improving the human condition through the development of innovative therapies. Nominees are selected from among those medicines and devices approved by the FDA in the last five years.
...
"BELVIQ is a novel single agent internally discovered at Arena, and was the first new prescription weight-loss treatment approved by the FDA in 13 years," said Dominic P. Behan, Ph.D., Arena's Executive Vice President and Chief Scientific Officer. "Nomination for the Prix Galien is a prestigious honor that is underscored by the caliber of innovative therapies included alongside BELVIQ in this category."
The Prix Galien Award ceremony will be held in New York City on October 22, 2013.
About BELVIQ® (lorcaserin HCl) CIV
BELVIQ (pronounced BEL-VEEK) is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of:
30 kg/m2 or greater (obese), or
27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes).
SAN DIEGO, July 25, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that BELVIQ® (lorcaserin HCl) has been nominated for the 2013 Prix Galien USA Award in the Best Pharmaceutical Agent category. BELVIQ is approved by the US Food and Drug Administration (FDA) for chronic weight management in adults.
The Prix Galien Award is considered one of the biomedical industry's top accolades, as it recognizes outstanding achievements in improving the human condition through the development of innovative therapies. Nominees are selected from among those medicines and devices approved by the FDA in the last five years.
...
"BELVIQ is a novel single agent internally discovered at Arena, and was the first new prescription weight-loss treatment approved by the FDA in 13 years," said Dominic P. Behan, Ph.D., Arena's Executive Vice President and Chief Scientific Officer. "Nomination for the Prix Galien is a prestigious honor that is underscored by the caliber of innovative therapies included alongside BELVIQ in this category."
The Prix Galien Award ceremony will be held in New York City on October 22, 2013.
About BELVIQ® (lorcaserin HCl) CIV
BELVIQ (pronounced BEL-VEEK) is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of:
30 kg/m2 or greater (obese), or
27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes).
Advertisement
You have just read the article News for today's that category by title Exciting Nomination for Belviq. You can bookmark this page with a URL http://news-these-days.blogspot.com/2013/07/exciting-nomination-for-belviq.html. Thank you!
Posted by: Tukiyooo
Exciting Nomination for Belviq Updated at :
2:02 PM
Thursday, July 25, 2013
Post a Comment